SCHEMBL25371447

SCHEMBL25371447

CCC(=O)N1N=C(c2c(C)c3ccsc3[nH]c2=O)CC1c1ccc(C)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ RAD51 Q06609 4/20 0.44
▸ KDM4E B2RXH2 3/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ HPGD P15428 1/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ GAA P10253 1/20 0.42
▸ XBP1 P17861 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ GRIN2D O15399 1/20 0.40
▸ GRIN2C Q14957 1/20 0.40
▸ RXRA P19793 1/20 0.40
▸ RXRB P28702 1/20 0.40
▸ RXRG P48443 1/20 0.40
▸ KIF11 P52732 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25432232 0.91 KDM4E (0.43) RAD51KDM4EALDH1A1HPGDMEN1
SCHEMBL25432457 0.91 KDM4E (0.43) RAD51KDM4EALDH1A1HPGDMEN1
SCHEMBL25371280 0.91 KDM4E (0.43) RAD51KDM4EALDH1A1HPGDMEN1
SCHEMBL25434187 0.89 RAD51 (0.43) RAD51KDM4EALDH1A1HPGDMEN1
SCHEMBL26064225 0.87 MEN1 (0.58) RAD51KDM4EALDH1A1HPGDMEN1
SCHEMBL26064226 0.87 MEN1 (0.58) RAD51KDM4EALDH1A1HPGDMEN1
SCHEMBL25432110 0.87 MEN1 (0.58) RAD51KDM4EALDH1A1HPGDMEN1
SCHEMBL25432966 0.85 RAD51 (0.58) RAD51MEN1KMT2A
SCHEMBL26064199 0.85 RAD51 (0.58) RAD51MEN1KMT2A
SCHEMBL26064198 0.85 RAD51 (0.58) RAD51MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250145601-A1 NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS SATYA THERAPEUTICS, INC. 2025-05-08 — — US claimed
EP-4482831-A1 NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS Satya Therapeutics, Inc. (US) 2025-01-01 — — EP claimed
WO-2023161782-A1 NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS SATYARX PHARMA INNOVATIONS PVT LTD (IN) 2023-08-31 — — WO claimed
US-20250145601-A1 NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS SATYA THERAPEUTICS, INC. 2025-05-08 — — US disclosed
EP-4482831-A1 NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS Satya Therapeutics, Inc. (US) 2025-01-01 — — EP disclosed
WO-2023161782-A1 NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS SATYARX PHARMA INNOVATIONS PVT LTD (IN) 2023-08-31 — — WO disclosed
WO-2023161782-A1 NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS SATYARX PHARMA INNOVATIONS PVT LTD (IN) 2023-08-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145601-A1 NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS RAD51, ERCC4, ERCC2 RAD51 1/4885KDM4E 3731/4885ALDH1A1 4307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback